QQQ   284.73 (+0.11%)
AAPL   117.25 (-0.22%)
MSFT   213.89 (-0.35%)
FB   279.64 (+4.51%)
GOOGL   1,568.80 (+2.54%)
AMZN   3,215.79 (-0.04%)
TSLA   420.98 (-0.23%)
NVDA   543.49 (-0.43%)
BABA   312.02 (+0.71%)
CGC   19.23 (+1.85%)
GE   7.29 (-0.68%)
MU   53.32 (-0.39%)
AMD   81.62 (+0.07%)
T   26.82 (+0.22%)
F   7.76 (+0.26%)
ACB   4.62 (+1.32%)
GILD   60.34 (-0.38%)
NFLX   502.51 (-4.36%)
BA   167.00 (-0.14%)
BAC   24.26 (+0.50%)
DIS   124.86 (-0.07%)
QQQ   284.73 (+0.11%)
AAPL   117.25 (-0.22%)
MSFT   213.89 (-0.35%)
FB   279.64 (+4.51%)
GOOGL   1,568.80 (+2.54%)
AMZN   3,215.79 (-0.04%)
TSLA   420.98 (-0.23%)
NVDA   543.49 (-0.43%)
BABA   312.02 (+0.71%)
CGC   19.23 (+1.85%)
GE   7.29 (-0.68%)
MU   53.32 (-0.39%)
AMD   81.62 (+0.07%)
T   26.82 (+0.22%)
F   7.76 (+0.26%)
ACB   4.62 (+1.32%)
GILD   60.34 (-0.38%)
NFLX   502.51 (-4.36%)
BA   167.00 (-0.14%)
BAC   24.26 (+0.50%)
DIS   124.86 (-0.07%)
QQQ   284.73 (+0.11%)
AAPL   117.25 (-0.22%)
MSFT   213.89 (-0.35%)
FB   279.64 (+4.51%)
GOOGL   1,568.80 (+2.54%)
AMZN   3,215.79 (-0.04%)
TSLA   420.98 (-0.23%)
NVDA   543.49 (-0.43%)
BABA   312.02 (+0.71%)
CGC   19.23 (+1.85%)
GE   7.29 (-0.68%)
MU   53.32 (-0.39%)
AMD   81.62 (+0.07%)
T   26.82 (+0.22%)
F   7.76 (+0.26%)
ACB   4.62 (+1.32%)
GILD   60.34 (-0.38%)
NFLX   502.51 (-4.36%)
BA   167.00 (-0.14%)
BAC   24.26 (+0.50%)
DIS   124.86 (-0.07%)
QQQ   284.73 (+0.11%)
AAPL   117.25 (-0.22%)
MSFT   213.89 (-0.35%)
FB   279.64 (+4.51%)
GOOGL   1,568.80 (+2.54%)
AMZN   3,215.79 (-0.04%)
TSLA   420.98 (-0.23%)
NVDA   543.49 (-0.43%)
BABA   312.02 (+0.71%)
CGC   19.23 (+1.85%)
GE   7.29 (-0.68%)
MU   53.32 (-0.39%)
AMD   81.62 (+0.07%)
T   26.82 (+0.22%)
F   7.76 (+0.26%)
ACB   4.62 (+1.32%)
GILD   60.34 (-0.38%)
NFLX   502.51 (-4.36%)
BA   167.00 (-0.14%)
BAC   24.26 (+0.50%)
DIS   124.86 (-0.07%)
Log in
FRA:MRK

Merck KGaA News Headlines

€124.60
+0.30 (+0.24 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
€124.25
Now: €124.60
€125.75
50-Day Range
€113.25
MA: €123.75
€131.00
52-Week Range
€76.60
Now: €124.60
€115.00
Volume352,191 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Merck KGaA (FRA MRK) News Headlines Today

Source:
DateHeadline
Merck KGaA (FRA:MRK) Given a €127.00 Price Target at Morgan StanleyMerck KGaA (FRA:MRK) Given a €127.00 Price Target at Morgan Stanley
americanbankingnews.com - October 21 at 7:45 AM
Merck KGaA (FRA:MRK) PT Set at €135.00 by Sanford C. BernsteinMerck KGaA (FRA:MRK) PT Set at €135.00 by Sanford C. Bernstein
americanbankingnews.com - October 21 at 6:22 AM
Mercks 15-valent pneumonia vaccine successful in two more late-stage studiesMerck's 15-valent pneumonia vaccine successful in two more late-stage studies
seekingalpha.com - October 20 at 7:36 AM
Mercks Keytruda/chemo combo shows durable, sustained benefit in long term lung cancer studyMerck's Keytruda/chemo combo shows durable, sustained benefit in long term lung cancer study
seekingalpha.com - October 16 at 6:55 PM
Merck KGaA (FRA:MRK) Given Consensus Recommendation of "Hold" by BrokeragesMerck KGaA (FRA:MRK) Given Consensus Recommendation of "Hold" by Brokerages
americanbankingnews.com - October 16 at 1:34 AM
Merck KGaA (FRA:MRK) Given a €125.00 Price Target at BarclaysMerck KGaA (FRA:MRK) Given a €125.00 Price Target at Barclays
americanbankingnews.com - October 13 at 6:23 AM
A German drugmaker just increased its stake in this Md. biopharma — and it showed in the stock priceA German drugmaker just increased its stake in this Md. biopharma — and it showed in the stock price
bizjournals.com - October 12 at 4:56 PM
Merck KGaA (FRA:MRK) Shares Cross Above Two Hundred Day Moving Average of $107.79Merck KGaA (FRA:MRK) Shares Cross Above Two Hundred Day Moving Average of $107.79
americanbankingnews.com - October 9 at 2:46 AM
Merck HIV combo regimen shows sustained benefit in mid-stage HIV studyMerck HIV combo regimen shows sustained benefit in mid-stage HIV study
seekingalpha.com - October 8 at 12:47 PM
Merck Mid-stage HIV Study On Islatravir- Doravirine Shows Viral Suppression MaintainedMerck Mid-stage HIV Study On Islatravir- Doravirine Shows Viral Suppression Maintained
nasdaq.com - October 8 at 12:47 PM
New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%
baystreet.ca - October 7 at 11:43 AM
Merck Inc (MRK) EVP, Global Svcs & CFO Robert M Davis Sold $20.4 million of SharesMerck Inc (MRK) EVP, Global Svcs & CFO Robert M Davis Sold $20.4 million of Shares
uk.finance.yahoo.com - October 6 at 10:49 PM
Merck Banks on Keytruda, Pipeline & Deals Amid Generic WoesMerck Banks on Keytruda, Pipeline & Deals Amid Generic Woes
nasdaq.com - October 2 at 12:44 PM
Merck KGaA (FRA:MRK) Given a €139.00 Price Target by Independent Research AnalystsMerck KGaA (FRA:MRK) Given a €139.00 Price Target by Independent Research Analysts
americanbankingnews.com - October 1 at 10:55 AM
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal CancerCelyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
nasdaq.com - September 29 at 7:30 PM
Merck KGaA (FRA:MRK) Given a €102.00 Price Target by Goldman Sachs Group AnalystsMerck KGaA (FRA:MRK) Given a €102.00 Price Target by Goldman Sachs Group Analysts
americanbankingnews.com - September 28 at 6:06 AM
DZ Bank Reaffirms Buy Rating for Merck KGaA (FRA:MRK)DZ Bank Reaffirms Buy Rating for Merck KGaA (FRA:MRK)
americanbankingnews.com - September 28 at 6:06 AM
Merck Enbrel biosimilar OKd in Canada for four new usesMerck Enbrel biosimilar OK'd in Canada for four new uses
seekingalpha.com - September 15 at 8:56 AM
Merck: Health Canada Approves BRENZYS For Four New IndicationsMerck: Health Canada Approves BRENZYS For Four New Indications
nasdaq.com - September 15 at 8:56 AM
Merck (Finally) Starts a Clinical Trial of its Coronavirus VaccineMerck (Finally) Starts a Clinical Trial of its Coronavirus Vaccine
fool.com - September 14 at 12:16 AM
Merck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 TrialsMerck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 Trials
nasdaq.com - September 8 at 9:19 AM
Merck To Present New Data From Oncology Development Program At ESMO Virtual CongressMerck To Present New Data From Oncology Development Program At ESMO Virtual Congress
nasdaq.com - September 2 at 10:11 AM
Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?
nasdaq.com - August 30 at 2:53 PM
Merck : Phase 3 Study Of KEYTRUDA - Chemotherapy On Metastatic Esophageal Cancer Meets Main GoalMerck : Phase 3 Study Of KEYTRUDA - Chemotherapy On Metastatic Esophageal Cancer Meets Main Goal
nasdaq.com - August 19 at 8:20 AM
Merck in-licenses NASH candidate from Hanmi PharmaceuticalMerck in-licenses NASH candidate from Hanmi Pharmaceutical
seekingalpha.com - August 4 at 7:29 AM
Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 PipelineGoldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
www.msn.com - August 3 at 1:09 PM
Merck Posts Second-Quarter Earnings Beat and Lifts GuidanceMerck Posts Second-Quarter Earnings Beat and Lifts Guidance
www.thestreet.com - July 31 at 8:04 AM
Pharma giant Merck raises 2020 outlook, saying the worst of the coronavirus impact is behind itPharma giant Merck raises 2020 outlook, saying the worst of the coronavirus impact is behind it
www.cnbc.com - July 31 at 8:04 AM
Earnings Preview: Merck (MRK) Q2 Earnings Expected to DeclineEarnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
www.nasdaq.com - July 24 at 2:53 PM
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer FightNew Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
www.marketwatch.com - July 21 at 8:41 AM
Novocure teams up with Merck in lung cancer studyNovocure teams up with Merck in lung cancer study
seekingalpha.com - July 15 at 9:08 AM
Merck: Amazing Oncology Division, Underwhelming Dividend OpportunityMerck: Amazing Oncology Division, Underwhelming Dividend Opportunity
seekingalpha.com - July 9 at 1:04 PM
Pfizers sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU NodPfizer's sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU Nod
finance.yahoo.com - July 3 at 5:51 PM
Mercks Keytruda Wins FDA Nod for Squamous Cell Skin CancerMerck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
www.nasdaq.com - June 25 at 1:18 PM
Merck teams up with Yumanity in neurodegenerative diseasesMerck teams up with Yumanity in neurodegenerative diseases
seekingalpha.com - June 24 at 12:14 PM
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: VirtualMerck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
www.benzinga.com - June 24 at 7:13 AM
MORNING BID-Counteracting forcesMORNING BID-Counteracting forces
finance.yahoo.com - June 24 at 7:13 AM
Mercks Pneumococcal Vaccine Meets Goal in Two Adult StudiesMerck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
www.nasdaq.com - June 23 at 3:55 PM
Merck: FDA Approves Second Biomarker-Based Indication For KEYTRUDAMerck: FDA Approves Second Biomarker-Based Indication For KEYTRUDA
www.nasdaq.com - June 17 at 10:23 AM
Mercks Steglatro Non-Inferior in Cardiovascular Outcomes StudyMerck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
www.nasdaq.com - June 17 at 10:23 AM
FDA OKs Mercks Keytruda for second application based on biomarkerFDA OKs Merck's Keytruda for second application based on biomarker
seekingalpha.com - June 16 at 5:55 PM
MORNING BID-About-turnMORNING BID-About-turn
finance.yahoo.com - June 16 at 7:54 AM
MORNING BID-Fed upMORNING BID-Fed up
finance.yahoo.com - June 10 at 4:32 AM
Mercks Keytruda flunks first-line bladder cancer studyMerck's Keytruda flunks first-line bladder cancer study
seekingalpha.com - June 9 at 6:00 PM
Merck Over Roche For 25% Gains?Merck Over Roche For 25% Gains?
www.forbes.com - June 9 at 12:59 PM
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia ...FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia ...
www.businesswire.com - June 5 at 7:36 AM
MORNING BID-Warm glow for marketsMORNING BID-Warm glow for markets
finance.yahoo.com - June 5 at 7:36 AM
Merck Announces Third-Quarter 2020 DividendMerck Announces Third-Quarter 2020 Dividend
www.businesswire.com - May 26 at 1:33 PM
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
www.businesswire.com - May 26 at 8:03 AM
Merck Jumps Into Search for Covid-19 Vaccine and TreatmentMerck Jumps Into Search for Covid-19 Vaccine and Treatment
www.thestreet.com - May 26 at 8:03 AM
This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.